Travere Therapeutics Inc. (TVTX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Travere Therapeutics: Filspari Is Becoming A Rare Kidney Disease Platform
Travere Therapeutics has transitioned into a rare disease commercial platform, driven by FILSPARI's strong growth in IgAN and recent FSGS approval. TVTX's premium valuation is justified by rapid revenue expansion, significant operating leverage, and strategic pipeline moves like the civorebrutinib acquisition. FILSPARI's unique positioning and first-mover advantage in FSGS, alongside a simplified REMS, support continued market penetration despite a competitive IgAN landscape.
Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines Transcript
Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines Transcript
Travere Therapeutics, Inc. (TVTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Travere Therapeutics, Inc. (TVTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Travere Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 261 | $5,077.83 | $14,741.28 | $9,663.45 | 190.31% |
 Farallon Capital Farallon Capital Management LLC | 12,000 | $177,600 | $679,452 | $501,852 | 282.57% |
| BG Bart Gancher Intech Investment Management LLC | 22,541 | $664,823.54 | $1.27M | $608,445.42 | 91.52% |
 Anthony Scaramucci SkyBridge Capital II LLC | 4.9M | $105.42M | $277M | $171.58M | 162.77% |
| PF Phillip Fitzsimmons Hennion & Walsh Asset Management Inc. | 171,470 | $6.91M | $9.71M | $2.8M | 40.51% |
Travere Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Vamil Divan Guggenheim | 10,238.92 | $579,420.69 | $583,209.09 | $3,788.4 | 0.65% |
 Tyler Van Buren TD Cowen | 452.24 | $20,455.44 | $25,660.27 | $5,204.83 | 25.44% |
 Yigal Nochomovitz Citigroup | 92.47 | $4,987.57 | $5,111.51 | $123.94 | 2.48% |
Travere Therapeutics Inc. (TVTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Travere Therapeutics Inc. ever had a stock split?
Travere Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Eric Dube CEO | NASDAQ (NMS) Exchange | 89422G107 CUSIP |
| US Country | 497 Employees | - Last Dividend | 2 Nov 2012 Last Split | 8 Nov 2012 IPO Date |
Overview
Travere Therapeutics, Inc. is a biopharmaceutical company dedicated to the identification, development, commercialization, and delivery of treatments for rare diseases. The company's commitment to addressing unmet medical needs in the rare disease community guides its research and product pipeline. Founded in 2008 and based in San Diego, California, Travere Therapeutics has evolved its focus and portfolio, leading to its rebranding from Retrophin, Inc. in November 2020. The company has established partnerships with key scientific and patient advocacy organizations to propel its research and development efforts. These collaborations, including agreements with the National Institutes of Health's National Center for Advancing Translational Sciences, CDG Care, and the Alagille Syndrome Alliance, underscore its dedication to discovering therapies for complex conditions, such as NGLY1 deficiency and Alagille syndrome.
Products and Services
- Chenodal
A synthetic oral form of chenodeoxycholic acid, Chenodal is designed for the treatment of radiolucent stones in the gallbladder. By replicating and enhancing the action of a naturally occurring bile acid, Chenodal contributes to the dissolution of gallstones that do not require surgical intervention, providing a non-invasive treatment option for patients suffering from this condition.
- Cholbam
Cholbam, a cholic acid capsule, serves as a therapy for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and it acts as an adjunctive treatment for patients with peroxisomal disorders. This medication addresses a critical need for individuals with rare metabolic disorders, offering a pathway to manage these conditions and improve quality of life.
- Thiola and Thiola EC
These tiopronin tablets are crafted for the treatment of homozygous cystinuria, a rare condition characterized by recurrent cystine kidney stones. Thiola and Thiola EC work by reducing the concentration of cystine in the urine, thereby decreasing the risk of stone formation. This therapeutic approach provides essential relief and prevention for individuals grappling with this challenging and recurrent issue.
- Sparsentan
Currently in Phase III clinical trial, Sparsentan represents a pioneering effort in the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. As a dual-acting antagonist, it targets specific pathways that contribute to the progression of these serious kidney disorders, offering hope for a more effective treatment option than currently available therapies.
- TVT-058
A novel investigational human enzyme replacement candidate, TVT-058 is in Phase I/II clinical trials for the treatment of classical homocystinuria. This genetic disorder leads to the accumulation of homocysteine in the body, posing severe health risks. TVT-058 aims to provide a direct therapeutic mechanism to reduce these levels, addressing the root cause of the condition.
